Axogen, Inc.
Company Stats
- Market Cap
- $2.3B
- as of Sep 30, 2026
- Shares Outstanding
- 53.8M
- Free Float
- 90.7%
Income Statement
- Revenue
- $225.2M
- Operating Income
- -$7.8M
- Net Income
- -$15.7M
- EBITDA
- -$1.2M
- Non-cash Impairment
- $64,000
- Revenue Growth, 3Y
- 17.6%
- FCF Margin, 3Y Avg
- -4.3%
- FCF Margin, Worst Year
- -12.3%
Cash Flow
- Free Cash Flow
- -$2.9M
- FCF Yield
- -0.1%
- Owner FCF Yield
- -1.5%
Balance Sheet
- Cash & Equivalents
- $35.5M
Returns & Capital
- SBC, 3Y Avg
- $20.1M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $225.2M | -$2.9M | -1.3% |
| FY2024 | $187.3M | $1.4M | 0.8% |
| FY2023 | $159.0M | -$19.6M | -12.3% |
| FY2022 | $138.6M | -$36.1M | -26.1% |
| FY2021 | $127.4M | -$41.2M | -32.4% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 7, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Axogen to Buy BioCircuit Technologies in $200 Million Cash Deal
Healthcare Earnings: Demand Surges, Costs Bite Back